Internship

Regulatory/Quality Co-Op

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Durham, NC, USA

Hybrid working environment.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Data Analysis
Requirements
  • Pursuing a Bachelor's degree in Biotechnology, Bioengineering, Biochemistry, or related field.
  • Prior industry internship or academic lab-based research experience is preferred.
  • The candidate should have a solid academic foundation in science and laboratory coursework (examples: biology/chemistry/biochemistry, biochemical/bioengineering, microbiology, tissue culture, molecular biology, etc.)
  • A team player who is curious, motivated to learn, organized, and has good communication skills.
  • Note, this role will function within a hybrid (partially remote, partially onsite) working environment, and requires a self-motivated individual.
Responsibilities
  • Review executed batch records, associated testing records, and other documentation to ensure that all steps have been executed correctly, and that all limits and specifications have been met.
  • Review deviations, change controls and Corrective and Preventive Actions (CAPAs) for appropriateness, completeness.
  • Support the draft and review of Standard Operating Procedures (SOPs) and related GMP documents.
  • Provide Quality Assurance (QA) support to contract manufacturing operations (attend meetings, person in plant review and approval of Contract Manufacturing Organization (CMO) documentation.)
  • Monitors and trends batch record errors, provides management with quality indicator data, and collaborates with stakeholders to reduce sources of error.
  • Participates in system improvement initiatives to optimize the business processes and practices within Veeva.
  • Participates in projects to support Supplier Management and Quality Systems department holistically.
  • Assess document metadata within Veeva for missing data and facilitate and department clean-up.
  • Assist in organization of the Document Archival Room and enter paper archives into a database for tracking.
  • Assist in logbook cleanup around site.
  • Remove all learner roles and manager associations for inactive/ineligible users in Veeva.
  • The Quality Control Co-op will have responsibility for projects associated with the stability of a product.
  • Under the guidance of their mentor, will be accountable for initiating a stability data trending sheet, compiling all the stability data into our document system, recording all the data in the trending sheet, performing trend analysis on the data, and documenting the extension of shelf-life of the product base on the data.
  • Perform tasks in the Quality Control laboratory consisting of sample log in, reagent management, buffer preparation and sample testing.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and support for their projects. The ultimate goal of Beam Therapeutics is to advance scientific research and deliver effective, long-lasting treatments for patients suffering from genetic conditions.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

-2%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.

Help us improve and share your feedback! Did you find this helpful?